Bio-Rad Laboratories, Inc.
BIO US
BIO USBio-Rad Laboratories, Inc.
United States Composite279.73
- Business
- Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Company News
Bio-Rad Laboratories (NYSE:BIO shareholders incur further losses as stock declines 14% this week, taking three-year losses to 53%
Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition
Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition
OncoCyte Corp (OCX) Q4 2023 Earnings Call Transcript Highlights: Strategic Partnerships and ...
Q4 2023 OncoCyte Corp Earnings Call
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
Waters (WAT) Boosts Waters Operating Segment With HPLC System
Bio-Rad’s Chief Operating Officer Andrew Last to Retire
RBC Capital Reaffirms Their Buy Rating on Bio-Rad Laboratories (BIO)
Why Is Perrigo (PRGO) Up 19.1% Since Last Earnings Report?
Why Is Perrigo (PRGO) Up 19.1% Since Last Earnings Report?
Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer
Green Thumb Industries Inc. (GTBIF) Soars 11.3%: Is Further Upside Left in the Stock?
Green Thumb Industries Inc. (GTBIF) Soars 11.3%: Is Further Upside Left in the Stock?
Bio-Rad (BIO) Suffers due to BioPharma Softness, Stiff Competition
Bio-Rad (BIO) Suffers due to BioPharma Softness, Stiff Competition